STAAR SURGICAL CO
STAANASDAQTrading Snapshot
- Day Range
- $24.61 โ $25.52
- 52-Week Range
- $15.59 โ $35.87
- Volume (shares)
- 453,587
- Avg Volume (shares)
- โ
- Shares Outstanding
- 50.1M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $239M
- Last Q Revenue
- $94M
- P/E Ratio
- 317.0
- P/S Ratio
- 3.6x
- EPS (TTM)
- $0.07
- Dividend Yield
- โ
- Dilution (1yr)
- +4.0%
STAAR SURGICAL CO
STAAAbout STAAR SURGICAL CO
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Ratings
โLatest News & Updates

STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (โSTAARโ or the โCompanyโ) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamerยฎ Lenses (EVO ICLโข) for vision correctio

Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If you are a current sh

B. Riley Wealth Advisors Inc. Makes New $546,000 Investment in STAAR Surgical Company $STAA
B. Riley Wealth Advisors Inc. bought a new stake in STAAR Surgical Company (NASDAQ: STAA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2

STAAR Surgical Names Andrew Pilon as Vice President of Business Development
STAAR Surgical Company (รขยยSTAARรขยย or the รขยยCompanyรขยย) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamerร Lenses

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday
That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.